Results 51 to 60 of about 169,996 (318)
JAMA Neurology, 2019 Importance Dual antiplatelet therapy with clopidogrel and aspirin is effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA).
Yuesong Pan +13 more
semanticscholar +1 more source
Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome
Circulation, 2020 Supplemental Digital Content is available in the text. Background: The comparative efficacy and safety of ticagrelor versus clopidogrel in older patients with myocardial infarction (MI) has received limited study.
K. Szummer +8 more
semanticscholar +1 more source
Clopidogrel: A multifaceted affair [PDF]
The Journal of Clinical Pharmacology, 2014 AbstractClopidogrel has been the therapy of choice, combined with aspirin, against platelet aggregation in patients at risk of suffering a vascular thrombotic event. Not all patients respond equally to clopidogrel, an observation that has led to searching for a test that, in the clinical setting, could predict patients' “resistance” to therapy.
Antonio Tugores +1 more
openaire +4 more sources
Emerging Strategies for Platelet‐Modified Nanoparticles in Targeted Tumor Therapy
Advanced NanoBiomed Research, EarlyView.This review highlights innovative strategies using platelet‐modified nanoparticles to target tumors more precisely. By mimicking platelet functions, these biomimetic carriers improve tumor homing, enhance drug delivery, and reduce immune clearance.
Chunyu Bai +5 more
wiley +1 more source
Clopidogrel in Orthopaedic patients: a review of current practice in Scotland
Thrombosis Journal, 2007 Background Clopidogrel bisulfate is an antiplatelet agent used to prevent ischaemic events in patients with vascular disease. Current guidelines recommend withholding clopidogrel for 7 days pre-operatively.
Bramley Diane +2 more
doaj +1 more source
BMC Cardiovascular Disorders, 2022 Backgrounds Remarkable interindividual variability in clopidogrel response is observed, genetic polymorphisms in P2RY12 and its signal pathway is supposed to affect clopidogrel response in CHD patients.
Yan-Jiao Zhang +6 more
doaj +1 more source
Reassessing Antiplatelet Resistance in Ischemic Stroke: Addressing Key Gaps in Precision Medicine Research. [PDF]
CNS Neurosci TherCNS Neuroscience &Therapeutics, Volume 31, Issue 10, October 2025.
Taha MA.
europepmc +2 more sources
Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities
Arthritis &Rheumatology, EarlyView.Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley +1 more source
Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy
Journal of the Formosan Medical Association, 2012 Clopidogrel is associated with a high incidence of upper gastrointestinal bleeding in high-risk patients. However, the characteristic upper gastrointestinal lesions in symptomatic clopidogrel users remain unclear.
Tzung-Jiun Tsai +14 more
doaj +1 more source
An Idiosyncratic Reaction to Clopidogrel [PDF]
The Permanente Journal, 2015 Clopidogrel is an irreversible antiplatelet agent belonging to the thienopyridine group that acts to antagonize the adenosine diphosphate P2Y12 receptor on platelets. It thus inhibits the activation of platelet glycoprotein GPIIb/IIIa complex, which is essential for fibrinogen—platelet complex formation.
Kapila, Aaysha +6 more
openaire +4 more sources